{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T19:42:01Z","timestamp":1772048521701,"version":"3.50.1"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","drugandalcoholdependence.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug and Alcohol Dependence"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.drugalcdep.2017.10.017","type":"journal-article","created":{"date-parts":[[2017,12,2]],"date-time":"2017-12-02T08:17:07Z","timestamp":1512202627000},"page":"111-117","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Long-acting intramuscular naltrexone for opioid use disorder: Utilization and association with multi-morbidity nationally in the Veterans Health Administration"],"prefix":"10.1016","volume":"183","author":[{"given":"Megan M.","family":"Kelly","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erin","family":"Reilly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy","family":"Qui\u00f1ones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nitigna","family":"Desai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Rosenheck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.drugalcdep.2017.10.017_bib0005","doi-asserted-by":"crossref","first-page":"3252","DOI":"10.1001\/archinte.160.21.3252","article-title":"Are patients at veterans affairs medical centers sicker? A comparative analysis of health status and medical resource use","volume":"160","author":"Agha","year":"2000","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.drugalcdep.2017.10.017_bib0010","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jsat.2015.10.003","article-title":"Extended-release naltrexone: a qualitative analysis of barriers to routine use","volume":"62","author":"Alanis-Hirsch","year":"2016","journal-title":"J. Subst. Abuse Treat."},{"issue":"Suppl. 8","key":"10.1016\/j.drugalcdep.2017.10.017_bib0015","first-page":"S235","article-title":"Cost and utilization outcomes of opioid-dependence treatments","volume":"17","author":"Baser","year":"2011","journal-title":"Am. J. Manag. Care"},{"key":"10.1016\/j.drugalcdep.2017.10.017_bib0020","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/papr.12097","article-title":"Prevalence of diagnosed opioid abuse and its economic burden in the Veterans Health Administration","volume":"14","author":"Baser","year":"2014","journal-title":"Pain Pract."},{"key":"10.1016\/j.drugalcdep.2017.10.017_bib0025","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/j.1526-4637.2011.01075.x","article-title":"Societal costs of prescription opioid abuse, dependence, and misuse in the United States","volume":"12","author":"Birnbaum","year":"2011","journal-title":"Pain Med."},{"key":"10.1016\/j.drugalcdep.2017.10.017_bib0030","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.drugalcdep.2012.12.013","article-title":"Probability and predictors of treatment-seeking for prescription opioid use disorders: a national study","volume":"131","author":"Blanco","year":"2013","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2017.10.017_bib0035","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/BF03391611","article-title":"Future of multi-morbidity research: how should understanding of multi-morbidity inform health system design?","volume":"32","author":"Boyd","year":"2010","journal-title":"Public Health Rev."},{"key":"10.1016\/j.drugalcdep.2017.10.017_bib0040","first-page":"1487","article-title":"Vital signs: overdoses of prescription opioid pain relievers?-United States, 1999\u20132008","volume":"60","author":"CDC","year":"2011","journal-title":"MMWR"},{"key":"10.1016\/j.drugalcdep.2017.10.017_bib0045","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.drugalcdep.2012.11.018","article-title":"National trends in pharmaceutical opioid related overdose deaths compared to other substance related overdose deaths: 1999\u20132009","volume":"131","author":"Calcaterra","year":"2013","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2017.10.017_bib0050","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0885-3924(01)00396-7","article-title":"Chronic pain prevalence and analgesic prescribing in a general medical population","volume":"23","author":"Clark","year":"2002","journal-title":"J. Pain Symptom Manag."},{"key":"10.1016\/j.drugalcdep.2017.10.017_bib0055","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1007\/s11524-008-9304-9","article-title":"Estimating the prevalence of injection drug use among black and white adults in large U.S. metropolitan areas over time (1992\u20132002): estimation methods and prevalence trends","volume":"85","author":"Cooper","year":"2008","journal-title":"J. Urban Health"},{"key":"10.1016\/j.drugalcdep.2017.10.017_bib0060","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jsat.2016.07.014","article-title":"A naturalistic evaluation of extended-release naltrexone in clinical practice in Missouri","volume":"70","author":"Crits-Christoph","year":"2016","journal-title":"J. Subst. Abuse Treat."},{"key":"10.1016\/j.drugalcdep.2017.10.017_bib0065","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/j.1360-0443.2010.03140.x","article-title":"Mortality among regular or dependent users of heroin and other opioids: a systematic review and meta-analysis of cohort studies","volume":"106","author":"Degenhardt","year":"2011","journal-title":"Addiction"},{"key":"10.1016\/j.drugalcdep.2017.10.017_bib0070","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/j.1521-0391.2011.00166.x","article-title":"Association of substance use and VA service-connected disability benefits with risk of homelessness among veterans","volume":"20","author":"Edens","year":"2011","journal-title":"Am. J. Addict."},{"key":"10.1016\/j.drugalcdep.2017.10.017_bib0075","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.cct.2016.06.003","article-title":"Injectable pharmacotherapy for opioid use disorders (IPOD)","volume":"49","author":"Farabee","year":"2016","journal-title":"Contemp. Clin. Trials"},{"key":"10.1016\/j.drugalcdep.2017.10.017_bib0080","first-page":"30504","article-title":"Do patient characteristics moderate the effect of extended-release naltrexone (XR-NTX) for opioid use disorder?","volume":"S0740\u20135472","author":"Friedmann","year":"2017","journal-title":"J. Subst. Abuse Treat."},{"key":"10.1016\/j.drugalcdep.2017.10.017_bib0085","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1111\/j.1526-4637.2006.00146.x","article-title":"Pain among veterans of operations enduring freedom and Iraqi freedom","volume":"7","author":"Gironda","year":"2006","journal-title":"Pain Med."},{"key":"10.1016\/j.drugalcdep.2017.10.017_bib0090","doi-asserted-by":"crossref","first-page":"19","DOI":"10.7205\/MILMED-D-13-00235","article-title":"Mental health in deployed and nondeployed veteran men and women in comparison with their civilian counterparts","volume":"179","author":"Hoglund","year":"2014","journal-title":"Mil. Med."},{"key":"10.1016\/j.drugalcdep.2017.10.017_bib0095","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/add.12333","article-title":"Treatment retention among patients randomized to buprenorphine\/naloxone compared to methadone in a multi-site trial","volume":"109","author":"Hser","year":"2014","journal-title":"Addiction"},{"key":"10.1016\/j.drugalcdep.2017.10.017_bib0100","series-title":"Global State of Harm Reduction: Key Issues for Broadening the Response","author":"International Harm Reduction Association,","year":"2010"},{"key":"10.1016\/j.drugalcdep.2017.10.017_bib0105","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1007\/s11920-010-0135-5","article-title":"Use of naltrexone to treat opioid addiction in a country in which methadone and buprenorphine are not available","volume":"12","author":"Krupitsky","year":"2010","journal-title":"Curr. Psychiatry Rep."},{"key":"10.1016\/j.drugalcdep.2017.10.017_bib0110","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1016\/S0140-6736(11)60358-9","article-title":"Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicenter, randomized trial","volume":"377","author":"Krupitsky","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.drugalcdep.2017.10.017_bib0115","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1111\/add.12208","article-title":"Injectable extended-release naltrexone (XR-NTX) for opioid dependence: long-term safety and effectiveness","volume":"108","author":"Krupitsky","year":"2013","journal-title":"Addiction"},{"key":"10.1016\/j.drugalcdep.2017.10.017_bib0120","doi-asserted-by":"crossref","first-page":"ES9","DOI":"10.36076\/ppj.2012\/15\/ES9","article-title":"Opioid epidemic in the United States","volume":"15","author":"Manchikanti","year":"2012","journal-title":"Pain Physician"},{"key":"10.1016\/j.drugalcdep.2017.10.017_bib0125","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.drugalcdep.2015.12.035","article-title":"Characteristics of veterans receiving buprenorphine vs methadone for opioid use disorder nationally in the Veterans Health Administration","volume":"160","author":"Manhapra","year":"2016","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2017.10.017_bib0130","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.drugpo.2013.10.004","article-title":"Every \u2018never\u2019 I ever said came true: transitions from opioid pills to heroin injecting","volume":"25","author":"Mars","year":"2014","journal-title":"Int. J. Drug Policy"},{"key":"10.1016\/j.drugalcdep.2017.10.017_bib0135","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1001\/jamapsychiatry.2017.0113","article-title":"Changes in US lifetime heroin use and heroin use disorder: prevalence from the 2001\u20132002 to 2012\u20132013 National Epidemiologic Survey on alcohol and related conditions","volume":"74","author":"Martins","year":"2017","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.drugalcdep.2017.10.017_bib0140","first-page":"30413","article-title":"Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population","volume":"S0740\u20135472","author":"Morgan","year":"2017","journal-title":"J. Subst. Abuse Treat."},{"key":"10.1016\/j.drugalcdep.2017.10.017_bib0145","first-page":"182","article-title":"Expanded conceptualization of multi-morbidity to encompass substance use disorders and other psychiatric illness","volume":"28","author":"North","year":"2016","journal-title":"Ann. Clin. Psychiatry"},{"key":"10.1016\/j.drugalcdep.2017.10.017_bib0150","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1007\/s00127-013-0753-4","article-title":"Racial and ethnic disparities in the use of antipsychotic medication: a systematic review and meta-analysis","volume":"48","author":"Puyat","year":"2013","journal-title":"Soc. Psychiatry Psychiatr. Epidemiol."},{"key":"10.1016\/j.drugalcdep.2017.10.017_bib0155","first-page":"940","article-title":"Association of mental health disorders with prescription opioids and high-risk opioid use in US veterans of Iraq and Afghanistan","volume":"307","author":"Seal","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.drugalcdep.2017.10.017_bib0160","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.jsat.2009.05.003","article-title":"Buprenorphine maintenance treatment in a primary care setting: outcomes at 1year","volume":"37","author":"Soeffing","year":"2009","journal-title":"J. Subst. Abuse Treat."},{"key":"10.1016\/j.drugalcdep.2017.10.017_bib0165","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1111\/j.1525-1497.2005.0228.x","article-title":"Buprenorphine retention in primary care","volume":"20","author":"Stein","year":"2005","journal-title":"J. Gen. Intern. Med."},{"key":"10.1016\/j.drugalcdep.2017.10.017_bib0170","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.drugalcdep.2011.10.016","article-title":"The impact of buprenorphine on treatment of opioid dependence in a medicaid population: recent service utilization trends in the use of buprenorphine and methadone","volume":"123","author":"Stein","year":"2012","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2017.10.017_bib0175","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1007\/s40263-013-0110-x","article-title":"Extended-release intramuscular naltrexone (VIVITROL\u00ae). A review of its use in the prevention of relapse to opioid dependence in detoxified patients","volume":"27","author":"Syed","year":"2013","journal-title":"CNS Drugs"},{"key":"10.1016\/j.drugalcdep.2017.10.017_bib0180","doi-asserted-by":"crossref","first-page":"217","DOI":"10.2165\/11597520-000000000-00000","article-title":"Current and potential pharmacological treatment options for maintenance therapy in opioid-dependent individuals","volume":"72","author":"Tetrault","year":"2012","journal-title":"Drugs"},{"key":"10.1016\/j.drugalcdep.2017.10.017_bib0185","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1001\/jama.2012.5265","article-title":"Designing health care for the most common chronic condition\u2013multi-morbidity","volume":"307","author":"Tinetti","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.drugalcdep.2017.10.017_bib0190","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1001\/jamainternmed.2014.2726","article-title":"Chronic pain and opioid use in US soldiers after combat deployment","volume":"174","author":"Toblin","year":"2014","journal-title":"JAMA Intern. Med."},{"key":"10.1016\/j.drugalcdep.2017.10.017_bib0195","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0277-9536(99)00338-X","article-title":"The effect of patient race and socio-economic status on physicians\u2019perceptions of patients","volume":"50","author":"van Ryn","year":"2000","journal-title":"Soc. Sci. Med."},{"key":"10.1016\/j.drugalcdep.2017.10.017_bib0200","series-title":"Naltrexone Extended-release Injectable Suspension Criteria for Use in Alcohol Use Disorder and Opioid Use Disorder","author":"Veterans Health Administration","year":"2014"},{"key":"10.1016\/j.drugalcdep.2017.10.017_bib0205","series-title":"WWAMI Rural Health Research Center. RUCA Data Version 2.0","author":"WWAMI Rural Health Research Center","year":"2014"},{"key":"10.1016\/j.drugalcdep.2017.10.017_bib0210","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1111\/j.1526-4637.2011.01134.x","article-title":"An analysis of the root causes for opioid-related overdose deaths in the United States","volume":"12","author":"Webster","year":"2011","journal-title":"Pain Med."}],"container-title":["Drug and Alcohol Dependence"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0376871617305653?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0376871617305653?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,8,9]],"date-time":"2022-08-09T20:56:20Z","timestamp":1660078580000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0376871617305653"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":42,"alternative-id":["S0376871617305653"],"URL":"https:\/\/doi.org\/10.1016\/j.drugalcdep.2017.10.017","relation":{},"ISSN":["0376-8716"],"issn-type":[{"value":"0376-8716","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-acting intramuscular naltrexone for opioid use disorder: Utilization and association with multi-morbidity nationally in the Veterans Health Administration","name":"articletitle","label":"Article Title"},{"value":"Drug and Alcohol Dependence","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drugalcdep.2017.10.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Published by Elsevier Ireland Ltd.","name":"copyright","label":"Copyright"}]}}